Brand-name medications (Wegovy, Zepbound) are FDA approved and manufactured by Novo Nordisk and Eli Lilly
They can develop personalized strategies that align with patients weight loss goals, offer nutritional guidance , and coordinate with other healthcare professionals when necessary
Patients who are likely to demonstrate long-term response to GLP-1 RAs will likely lose a significant amount of weight within the first month.203205 Patients who fail to lose weight on treatment initiation should be evaluated for side effects, cost, or other factors impairing medication adherence
(3) Clinical Gaps : While preclinical data (e.g., berberines 500 mg/kg dose in rats) are promising, human trials are sparse, with only cinnamon, coffee, and wheat fiber tested in modest cohorts
GLP- 1 stimulation also lowers blood sugar levels by inhibiting cell production of glucagon [68]
Diabetes 62: 23802385